In May we released a report co-authored with BIO and BioMedTracker. One of the key take-aways from the report is that patient selection biomarkers, if used successfully, can triple the Likelihood of Approval (LOA) for clinical studies. Here is the data:
Share this Image On Your Site
Please include attribution to amplion.com with this graphic.
To learn more about Amplion and BiomarkerBase: